Search Within

Katherine Marie Bell-McGuinn

Formats
  1. Meeting Abstract (32)
  2. Journal Article (27)
  3. Book Section (1)
Groups
  1. Gynecology Disease Management Team (35)
  2. Department of Medicine (34)
  3. Solid Tumor Oncology Division (34)
  4. GDMT, Medicine (32)
  5. Gynecologic Medicine Service (32)
  6. Surgery (9)

More Groups

People
  1. Carol Aghajanian (29)
  2. Jason Konner (13)
  3. Paul Sabbatini (11)
  4. William Tew (10)
  5. Martee Hensley (9)
  6. David Spriggs (8)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (4)
  5. 2017 (4)
  6. 2016 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Gynecologic Oncology (15)
  3. Clinical Cancer Research (7)
  4. Cancer Research (5)
  5. Annals of Oncology (4)
  6. Diagnostic Pathology of Ovarian Tumors (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier B.V. (15)
  3. American Association for Cancer Research (12)
  4. Oxford University Press (4)
  5. Elsevier Science, Inc. (2)
  6. Springer (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
    Journal Article

    Aghajanian, C.; Bell-McGuinn, K. M.; Burris, H. A. 3rd; Siu, L. L.; Stayner, L. A.; Wheler, J. J.; Hong, D. S.; Kurkjian, C.; Pant, S.; Santiago-Walker, A.; more...
    Investigational New Drugs (2018)

    Fulltext@MSK | Save
  • Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
    Journal Article

    Gray, H. J.; Bell-McGuinn, K.; Fleming, G. F.; Cristea, M.; Xiong, H.; Sullivan, D.; Luo, Y.; McKee, M. D.; Munasinghe, W.; Martin, L. P.
    Gynecologic Oncology (2018)

    Fulltext@MSK | Save
  • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
    Journal Article

    Oza, A. M.; Tinker, A. V.; Oaknin, A.; Shapira-Frommer, R.; McNeish, I. A.; Swisher, E. M.; Ray-Coquard, I.; Bell-McGuinn, K.; Coleman, R. L.; O'Malley, D. M.; more...
    Gynecologic Oncology (2017)

    Fulltext@MSK | Save
  • Integrative development of a TLR8 agonist for ovarian cancer chemoimmunotherapy
    Journal Article

    Monk, B. J.; Facciabene, A.; Brady, W. E.; Aghajanian, C. A.; Fracasso, P. M.; Walker, J. L.; Lankes, H. A.; Manjarrez, K. L.; Danet-Desnoyers, G. Ä H.; Bell-McGuinn, K. M.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852)
    Journal Article

    Thaker, P. H.; Salani, R.; Brady, W. E.; Lankes, H. A.; Cohn, D. E.; Mutch, D. G.; Mannel, R. S.; Bell-McGuinn, K. M.; Di Silvestro, P. A.; Jelovac, D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial
    Journal Article

    Swisher, E. M.; Lin, K. K.; Oza, A. M.; Scott, C. L.; Giordano, H.; Sun, J.; Konecny, G. E.; Coleman, R. L.; Tinker, A. V.; O'Malley, D. M.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC)
    Meeting Abstract

    Coleman, R. L.; Swisher, E. M.; Oza, A. M.; Scott, C. L.; Giordano, H.; Lin, K. K.; Konecny, G. E.; Tinker, A.; O'Malley, D. M.; Kristeleit, R. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
    Meeting Abstract

    Kristeleit, R. S.; Shapira-Frommer, R.; Oaknin, A.; Balmana, J.; Ray-Coquard, I. L.; Domchek, S.; Tinker, A. V.; Castro, C. M.; Welch, S.; Poveda, A. M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib
    Meeting Abstract

    McNeish, I. A.; Lin, K. K.; Sun, J. X.; Goble, S.; Oza, A.; Coleman, R. L.; Scott, C. L.; Konecny, G.; Tinker, A. V.; O'Malley, D. M.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • A phase 2, single arm study of iniparib in patients with BRCA1 or BRCA2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Journal Article

    Bell-McGuinn, K. M.; Konner, J. A.; Tew, W. P.; Hensley, M. L.; Iasonos, A.; Charpentier, E.; Mironov, S.; Sabbatini, P.; Aghajanian, C.
    International Journal of Gynecological Cancer (2016)

    Fulltext@MSK | Save